Fidelity Investments — 2024 Investments
3 investments dated 2024 · listed companies and verified rows first · show all
City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands.
BiotechMedical DevicesCambridge, US
Mark Keating, MD(Co-founder)Kotaro Nakanishi, PhD(Co-founder)Yukihide Tomari, PhD(Co-founder)Phillip Zamore, PhD(Co-founder)
Co-investorsAN Venture PartnersARCH Venture PartnersSofinnova VenturesCasdin CapitalInvusRock Springs Capital
Lightmatter is a product development firm that partners with companies to design and build digital products from concept through launch.
Developer ToolsHealthtechSaaSMountain View, US
Greg Hausheer(CEO and Founder)inBen Beecher(CTO and Founder)Nicholas Harris(Founder)inThomas Graham(Founder)inTrevor Moorman(COO)Mollie Fleury(Chief of Staff)
Co-investorsGV (Google Ventures)Spark CapitalT. Rowe PriceViking Global Investors
Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases.
BiotechDigital HealthHealthtech
Vishal Patelin
Co-investorsAtlas VentureBorealis VenturesBorealis VenturesMagnetic VenturesOrbiMedAscenta Capital+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.